Fig. 2
Individual baseline and 6-month post-dupilumab treatment scores for each SNOT-22 domain—nasal (a), otologic/facial pain (b), sleep (c), and emotional (d). Each line represents an individual patient.
Fig. 2 | Scientific Reports
Individual baseline and 6-month post-dupilumab treatment scores for each SNOT-22 domain—nasal (a), otologic/facial pain (b), sleep (c), and emotional (d). Each line represents an individual patient.
